These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22327486)

  • 1. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study.
    Pope E; Doria AS; Theriault M; Mohanta A; Laxer RM
    Dermatology; 2011; 223(4):363-9. PubMed ID: 22327486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial.
    Dytoc M; Wat H; Cheung-Lee M; Sawyer D; Ackerman T; Fiorillo L
    J Cutan Med Surg; 2015; 19(2):132-9. PubMed ID: 25775634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial.
    Theos AU; Cummins R; Silverberg NB; Paller AS
    Cutis; 2004 Aug; 74(2):134-8, 141-2. PubMed ID: 15379366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study.
    Berman B; Harrison-Balestra C; Perez OA; Viera M; Villa A; Zell D; Ramirez C
    J Drugs Dermatol; 2009 May; 8(5):455-8. PubMed ID: 19537368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients.
    Célestin Schartz NE; Chevret S; Paz C; Kerob D; Verola O; Morel P; Lebbé C
    J Am Acad Dermatol; 2008 Apr; 58(4):585-91. PubMed ID: 18068265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of recalcitrant skin ulcers as a side-effect of treatment with topical 5% imiquimod cream: report of two cases.
    Kalampalikis A; Goetze S; Elsner P
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1574-6. PubMed ID: 24456017
    [No Abstract]   [Full Text] [Related]  

  • 7. Imiquimod: a potential weapon against morphea and fibromatoses.
    Namazi MR
    J Drugs Dermatol; 2004; 3(4):362-3. PubMed ID: 15303778
    [No Abstract]   [Full Text] [Related]  

  • 8. Experience in treating molluscum contagiosum in children with imiquimod 5% cream.
    Bayerl C; Feller G; Goerdt S
    Br J Dermatol; 2003 Nov; 149 Suppl 66():25-9. PubMed ID: 14616342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical calcipotriene for morphea/linear scleroderma.
    Cunningham BB; Landells ID; Langman C; Sailer DE; Paller AS
    J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):211-5. PubMed ID: 9704831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
    Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream.
    Deeths MJ; Chapman JT; Dellavalle RP; Zeng C; Aeling JL
    J Am Acad Dermatol; 2005 Feb; 52(2):275-80. PubMed ID: 15692473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study.
    Kroft EB; Groeneveld TJ; Seyger MM; de Jong EM
    Am J Clin Dermatol; 2009; 10(3):181-7. PubMed ID: 19354332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First case series on the use of imiquimod for morphoea.
    Dytoc M; Ting PT; Man J; Sawyer D; Fiorillo L
    Br J Dermatol; 2005 Oct; 153(4):815-20. PubMed ID: 16181467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts.
    Komericki P; Akkilic-Materna M; Strimitzer T; Aberer W
    Sex Transm Dis; 2011 Mar; 38(3):216-8. PubMed ID: 20938374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of imiquimod cream 5% in the treatment of localized morphea.
    Man J; Dytoc MT
    J Cutan Med Surg; 2004; 8(3):166-9. PubMed ID: 15129316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study.
    Rosen T; Harting M; Gibson M
    Dermatol Surg; 2007 Apr; 33(4):427-31; discussion 431-2. PubMed ID: 17430376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
    Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
    J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
    Shaffelburg M
    J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.